Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $11.17.

CMPX has been the subject of several research analyst reports. Jefferies Financial Group boosted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday. D. Boral Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares during the period. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after acquiring an additional 19,095 shares during the period. Renaissance Technologies LLC lifted its position in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics during the 3rd quarter valued at about $79,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $3.90 on Tuesday. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.07. The stock’s 50-day simple moving average is $2.12 and its 200-day simple moving average is $1.74. The firm has a market cap of $536.60 million, a price-to-earnings ratio of -10.54 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, research analysts predict that Compass Therapeutics will post -0.35 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.